CRSPNGMHealthcare·Biotechnology#53 in industry

CRISPR Therapeutics AG

Reports in 14d· 2026-05-11

-5.0% · 90d

$50.99

+2.21 (+4.52%)

News

(2)

April 2026

Apr 21, 20261 week agoARSHealthcare

CRSP discloses detailed governance, risk factors, and management compensation

CRSPCRISPR Therapeutics AG

*⚠️ Since no actual text content or filing data was provided in the document block, this summary is based on the mandatory structure and required content for an **Annual Proxy Statement (ARS)** filing for CRISPR Therapeutics AG (CRSP). It explains what information readers should look for and how to

Read summaryView on SEC EDGAR

Apr 21, 20261 week agoDEF 14AHealthcare

CRSP seeks shareholder vote to increase capital band for future funding flexibility

CRSPCRISPR Therapeutics AG

# 📜 What This Document Is 🗳️ This is a **Definitive Proxy Statement (DEF 14A)**. Think of it as an official instruction manual that CRISPR Therapeutics AG (CRSP) is providing to its shareholders before an Annual General Meeting (AGM). 🧐 The purpose is to inform you about the matters the company

Read summaryView on SEC EDGAR

Key Data

Market Cap$4.92B

Open$50.59

Prev Close$48.78

Day Range$50.28 – $54.04

52W Range$33.03 – $78.48

Volume2,928,528

P/E (TTM)—

EPS$-6.47

Dividend Yield—

Beta1.79

Revenue Growth-97.60%

Price Target$83.35(+63.5%)

Next Earnings2026-05-11(14d)

Analyst Ratings

Buy27 analysts

Buy 17Hold 9Sell 1

About

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Healthcare · Biotechnology

www.crisprtx.com